. Military Space News .
EPIDEMICS
Scientists in China believe new drug can stop pandemic 'without vaccine'
By Qian Ye and Matthew Knight
Beijing (AFP) May 19, 2020

A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He said he hopes that the drug will be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralising antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

- Prevention and cure -

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.


Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola


Thanks for being here;
We need your help. The Space Media Network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceMediaNetwork Contributor
$5 Billed Once


credit card or paypal
SpaceMediaNetwork Monthly Supporter
$5 Billed Monthly


paypal only


EPIDEMICS
Injection better at HIV protection than daily pills: US researchers
Washington (AFP) May 18, 2020
Injecting people with a new, experimental drug every eight weeks provides better protection against HIV than daily pills that have revolutionized the fight against AIDS, US government researchers reported Monday. The National Institutes of Health released the preliminary results of a major clinical trial involving a drug called cabotegravir. The testing began more than three years ago in seven countries - including the United States, Brazil, Thailand and South Africa - and looked at men who have ... read more

Comment using your Disqus, Facebook, Google or Twitter login.



Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

EPIDEMICS
Boeing awarded $128.5M modification to GMD missile upgrade contract

US pulling Patriot missile batteries from Saudi

Northrop Grumman and Raytheon Missiles and Defense Partner on Next Generation Interceptor

US Army awards $6B contract to Lockheed Martin for PAC-3 MSE production

EPIDEMICS
Javelin JV completes the first F-Model missile

Raytheon nabs $19M for RAM missiles, GMLS launchers

Lockheed completes final test of Precision Strike Missile for Army

Northrop Grumman's Advanced Anti-Radiation Guided Missile continues to protect the US Navy

EPIDEMICS
Northrop Grumman supports government flight testing of the MQ-8C Fire Scout Radar

FLIR to supply Black Hornet Nano-UAV Systems for US Army's Soldier Borne Sensor Program

Textron nabs $20.7M contract modification for Navy drone program

Elbit Systems Introduces a UAS-Based Long-Range Maritime Rescue Capability

EPIDEMICS
IBCS Goes Agile

Northrop Grumman to rapidly develop net-centric gateway

Dominate the electromagnetic spectrum

L3Harris Technologies awarded third LRIP order on US Army's HMS Manpack IDIQ contract

EPIDEMICS
Prior COVID-19 diagnosis a disqualification for U.S. military service

Novel research speeds up threat detection, prevention for Army missions

21 SW enlisted keep critical USSF asset training churning during worldwide pandemic

FN America, Colt's awarded $383.3M to make M16A4s for Iraq, others

EPIDEMICS
Air Force awards $350M in contracts for road work at Alaska military bases

ARC Group nabs $7.2B DoD contract for moving services

Pentagon boosting US industrial capacity amid virus outbreak

Germany and France to develop joint next-generation army tank

EPIDEMICS
Russia, China boycott UN Security Council meeting on Syria

India, China in high-altitude fistfight at disputed border

Two Chinese vessels chase Japanese fishing boat near disputed islets

China says Japanese fishing boat near disputed islands was illegal

EPIDEMICS
Transporting energy through a single molecular nanowire

To make an atom-sized machine, you need a quantum mechanic

Magnetic nanoparticles help researchers remotely release adrenal hormones

New DNA origami motor breaks speed record for nano machines









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.